<DOC>
	<DOCNO>NCT02655822</DOCNO>
	<brief_summary>This phase 1/1b open-label , multicenter , dose-selection study CPI-444 , oral small molecule target adenosine-A2A receptor T-lymphocytes cell immune system . This trial study safety , tolerability , anti-tumor activity CPI-444 single agent combination atezolizumab , PD-L1 inhibitor various solid tumor . CPI-444 block adenosine bind A2A receptor . Adenosine suppress anti-tumor activity T cell immune cell .</brief_summary>
	<brief_title>Phase 1/1b Study Evaluate Safety Tolerability CPI-444 Alone Combination With Atezolizumab Advanced Cancers</brief_title>
	<detailed_description>This phase 1/1b open-label , multicenter , dose-selection study CPI-444 , oral small molecule target adenosine-A2A receptor T-lymphocytes cell immune system . This trial study safety , tolerability , anti-tumor activity CPI-444 single agent combination atezolizumab , intravenous PD-L1 inhibitor . CPI-444 block adenosine bind A2A receptor . Adenosine suppress anti-tumor activity T cell immune cell .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria 1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . 2 . Documented incurable cancer one follow histology : nonsmall cell lung cancer , malignant melanoma , renal cell cancer , triple negative breast cancer , colorectal cancer microsatellite instability ( MSI ) , bladder cancer . 3 . At least 1 measurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) . 4 . At least 1 5 prior systemic therapy advanced/recurrent progress disease . Exclusion Criteria 1 . History severe hypersensitivity reaction monoclonal antibody . 2 . Any active autoimmune disease document history serious autoimmune disease within past 5 year require immunosuppressive therapy . 3 . History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , clinical symptom active pneumonitis . 4 . The use investigational medication device 30 day prior screen throughout study prohibit . 5 . If patient currently receive denosumab , must discontinue prior enrollment . Substitution biphosphonates acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>MEL</keyword>
	<keyword>RCC</keyword>
	<keyword>TNBC</keyword>
	<keyword>Triple Negative Breast Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>CRC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>